Related Experiment Videos
Oral itraconazole therapy for superficial, subcutaneous, and systemic infections. A panoramic view
1University of Nevada School of Medicine, Las Vegas, USA.
Abstract:
The availability of the oral triazole agents itraconazole and fluconazole has revolutionized antifungal therapy. Although there are still some limitations and treatment failures, these agents have allowed for improved efficacy, increased safety, reduced morbidity, decreased mortality from systemic fungal disease, and a shift toward increased outpatient therapy for fungal infections that are not life-threatening. The treatment of superficial infections also has been enhanced by the development of effective intermittent and short-course regimens. Itraconazole exhibits broad-spectrum in vitro activity against several fungal organisms, including Trichophyton species, Candida albicans, Pityrosporum species, Aspergillus flavus, Aspergillus fumigatus, Blastomyces dermatitidis, Histoplasma capsulatum, Histoplasma capsulatum var duboisii, Sporothrix schenckii, and Cryptococcus neoformans. Animal model studies have confirmed the broad-spectrum in vivo activity of itraconazole. Multiple clinical studies and extensive clinical experience have substantiated the versatility of itraconazole, with good efficacy demonstrated in a wide variety of infections in humans. Itraconazole is approved for use in several countries for dermatomycoses, onychomycosis, oral-esophageal candidiasis, vaginal candidiasis, histoplasmosis, blastomycosis, aspergillosis, and fungal keratitis. Pulse therapy regimens for dermatomycoses and onychomycosis of the toenails or fingernails have been approved in several countries.
Insights
Oral triazole antifungals like itraconazole have transformed fungal infection treatment, offering better efficacy and safety. Itraconazole demonstrates broad-spectrum activity, proving effective against numerous fungal pathogens in clinical studies.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- Oral triazole antifungals, including itraconazole and fluconazole, have significantly advanced antifungal therapy.
- Despite limitations, these agents improve efficacy, safety, and reduce mortality from systemic fungal infections.
- Superficial fungal infections benefit from new intermittent and short-course treatment regimens.
Purpose of the Study:
- To review the therapeutic impact and clinical applications of oral triazole antifungal agents.
- To highlight the broad-spectrum activity and versatility of itraconazole in treating various fungal infections.
- To summarize the approved indications and treatment regimens for itraconazole.
Main Methods:
- Review of clinical studies and extensive clinical experience with itraconazole.
- Analysis of in vitro and animal model studies demonstrating itraconazole's antifungal spectrum.
- Compilation of approved uses and treatment regimens for itraconazole in different countries.
Main Results:
- Itraconazole exhibits broad-spectrum in vitro and in vivo activity against key fungal pathogens like Candida, Aspergillus, and dermatophytes.
- Clinical data confirms itraconazole's efficacy in treating a wide array of human fungal infections.
- Approved indications include dermatomycoses, onychomycosis, candidiasis, histoplasmosis, blastomycosis, aspergillosis, and fungal keratitis.
Conclusions:
- Oral triazole antifungals represent a major advancement in managing fungal diseases.
- Itraconazole is a versatile and effective agent for numerous superficial and systemic fungal infections.
- Novel therapeutic regimens, such as pulse therapy, enhance treatment options for conditions like onychomycosis.